Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 10/20 | 0.68 |
| ▸ | CRBN | Q96SW2 | 10/20 | 0.68 |
| ▸ | TNKS | O95271 | 6/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040966 | 0.83 | DDB1 (0.65) | DDB1CRBNTNKSTNKS2PARP1 | |
| SCHEMBL31040969 | 0.81 | CRBN (1.00) | DDB1CRBNTNKSTNKS2ALDH1A1 | |
| SCHEMBL31040954 | 0.79 | DDB1 (0.54) | DDB1CRBNTNKSTNKS2PARP1 | |
| SCHEMBL31040975 | 0.74 | CRBN (0.59) | DDB1CRBNTNKSTNKS2PARP1 | |
| SCHEMBL26683769 | 0.73 | DDB1 (0.57) | DDB1CRBNTNKSTNKS2PARP1 | |
| SCHEMBL31040948 | 0.73 | DDB1 (1.00) | DDB1CRBNTNKSTNKS2PARP1 | |
| SCHEMBL1068685 | 0.72 | ESR1 (0.42) | DDB1CRBNALDH1A1GAA | |
| SCHEMBL9047813 | 0.71 | IAPP (0.44) | ALDH1A1GAA | |
| SCHEMBL31040973 | 0.71 | CRBN (0.63) | DDB1CRBNTNKSTNKS2ALDH1A1 | |
| SCHEMBL29163083 | 0.70 | CRBN (0.54) | DDB1CRBNTNKSTNKS2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRBN, CUL1, CUL5 | DDB1 188/4885CRBN 1/4885TNKS 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.